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Abstract
This paper introduces HealthAgents, an EC-funded re-
searchprojecttoimprovetheclassiﬁcationofbraintumours
throughmulti-agentdecisionsupportover a distributednet-
work of local databases or Data Marts. HealthAgents will
not only develop new pattern recognition methods for a
distributed classiﬁcation and analysis of in vivo MRS and
ex vivo/in vitro HRMAS and DNA data, but also deﬁne a
method to assess the quality and usability of a new candi-
date local database containing a set of new cases, based on
a compatibility score.
1 Introduction
Brain tumours remain an important cause of morbidity
and mortality in Europe. Diagnosis using Magnetic Res-
onance Imaging (MRI) is non-invasive, but only achieves
60-90% accuracy depending on the tumour type and grade.
The current gold standardclassiﬁcation of brain tumoursby
biopsy and histopathologicalanalysis involvesinvasive sur-
gical procedure and incurs a risk.
Nowadays the diagnosis and treatment of brain tu-
mours is typically based on clinical symptoms, radiologi-
cal appearance and often a histopathological diagnosis of
a biopsy. However, treatment response of histologically
or radiologically-similar tumours can vary widely, particu-
larlyinchildren. MagneticResonanceSpectroscopy(MRS)
is a non-invasive technique for determining the tissue bio-
chemical composition (metabolomic proﬁle) of a tumour.
Additionally, the genomic proﬁle, determined using DNA
microarrays, facilitates the classiﬁcation of tumour grades
and types not trivially distinguished by morphologic ap-
pearance.
Thus, the HealthAgents project [13] entails the develop-
ment of a web-based decision support system (DSS) which
employs MRS and genomic proﬁles. This DSS will deploy
an agent-basedarchitecture in order to provide a distributed
diagnostic tool for brain tumours, implement data mining
techniques, transfer clinical data and extract information.
The distributed nature of our approachwill help the users to
observe local centre policies for sharing information whilst
allowing them to beneﬁt from the use of a distributed data
warehouse (d-DWH). Moreover,it will permit the design of
local classiﬁers targeting a speciﬁc patient population.
We argue that this new information for classifying tu-
mours along with clinical data, should be securely and eas-
ily accessible in order to improve the diagnosis and prog-
nosis of tumours. All data will be stored anonymously, and
securely through a network of data marts based on all this
information acquired and stored at centres throughout Eu-
rope. This network will grant bona-ﬁde access to an or-
ganisation in return for its contribution of clinical data to a
d-DWH/Decision Support System (d-DSS).
The rest of this paper is structured as follows. First, we
provide some background on the underlying technologies
for this project: brain tumour detection and agent technol-
ogy. Then we provide the architectural speciﬁcation. Fi-
nally, we conclude with our future work.
2 Background
2.1 Brain Tumour Diagnosis
Brain tumours remain an important cause of morbidity
and mortality and afﬂict an increasing percentage of aging
adults with a crude incidence rate of 8 per 100,000 inhabi-
tants in Europe [2]. In children over 1 year of age, brain tu-
mours are the most common solid malignancies that cause
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pathologies in a validated-DB from the INTERPRET
project [6]. These were obtained by averaging spectra nor-
malised to the Euclidian norm. The vertical axis is dis-
played in the same arbitrary units (a.u.) scale for all types.
The horizontal axis labels ppm values. Number of cases of
each typeinparentheses. Themost relevant metabolites are:
lipids, 0.9 and 1.29 ppm; N-acetyl-containing compounds,
2.03 ppm; acetate, 1.9 ppm; macromolecules and gluta-
mate/glutamine containing compounds, 2-2.5 ppm; crea-
tine, 3.03 ppm; choline-containing compounds, 3.21 ppm;
myo-inositol and glycine, 3.55 ppm; glutamate/glutamine-
containing compounds and alanine, 3.77 ppm. (Adapted
from Figure 4 of [12] c 2006 John Wiley & Sons Limited.
Reproduced with permission.)
disease-related death.
Diagnosis using Magnetic Resonance Imaging (MRI) is
non-invasive, but only achieves 60-90% accuracy depend-
ing on the tumour type and grade [5]. The current gold
standard classiﬁcation of a brain tumour by histopathologi-
cal analysis of biopsy is an invasive surgical procedure and
incurs a risk of 2.4-3.5% morbidity and 0.2-0.8% mortality,
in addition to healthcare costs and stress to patients. For tu-
moursthatevolveslowly(e.g. pilocyticastrocytomainchil-
dren), repeated biopsies may not be advisable or practical.
There is a need to improve brain tumour classiﬁcation, and
to provide non-invasive methods for brain tumour diagno-
sis and prognosis,to aid patientmanagementand treatment.
Three techniques are available to address these needs:
1. MagneticResonanceSpectroscopy(MRS)[4]isanon-
invasive technique that provides biochemical informa-
tion on tissue in vivo.
2. HR-MAS [8, 1] is applied to biopsies in vitro in order
to improve characterisation. Also, DNA microarray
analysis of biopsies can determine tumour phenotype
from gene expression proﬁles and predict better sur-
vival than classical histology [11, 10].
3. MRS, coupled with conventional MRI, provides
metabolite proﬁles of a single voxel (SV) of tumour
tissue [12, 4] (see Fig. 1). It also produces a molecular
image of particular tumour metabolites in 10 minutes
using multi-voxel (MV) techniques (Fig. 2).
2.2 Agent technology
Several modern complex distributed systems are com-
posed of customisable building blocks, known as agents.
Surveys on agent technology enumerate four important
characteristicsofagenttechnology[3]. First, agentspossess
an internal knowledge-based state that can be dynamically
altered. Second, they have dynamic reasoning capabilities
that determine their internal behaviour through constraints
orgoals. Third,theysustainacommunicationstatusthaten-
ables them to interact with agents or human entities. Last,
theyfeatureauniqueidentitythatprovidesroamingandser-
vice advertising capabilities.
Extensive research in agent systems has been conducted
in Europe, as evidenced by the reach of the AgentLink
membership [15]. Data mining agents present human re-
searchers with a set of potential hypotheses deduced from
the data sources. Thus, with the information explosion
caused by genomics and proteomics research, there is a
great need for automated information-gathering agents in
order to assist human researchers conducting automated or
semi-automated testing of data.
Recent initiatives have introduced the use of agents and
web servicesto genomeanalysisand decisionsupportin the
biomedical sciences [9]. On the other hand, the design of
web-based support has evolved into a mature research ﬁeld
for the integrationof domain speciﬁc studies with computer
science [16]. However, scant multi-disciplinary research
has been channelled to the distributed bioinformatics do-
main, where numerous databases and analysis tools are in-
dependently administered in geographically distinct locali-
ties, lending themselves almost ideally to the adoption of a
distributed intelligent multi-agent approach with enhanced
multi-layer security and a web-based user interface.
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Figure 2. (a) Molecular image of Cho (choline) concen-
tration distribution from CSI spectra of a patient with a
Glioblastoma (red indicates highest Cho levels in the tu-
mour) including the deconvoluted spectrum. (b) CSI spec-
tra from the rear cavity with a demyelisation lesion. The
nine spectra shown, from the selected green square, present
the most abnormal region bottom right (Images generated
using SIView 2.0 [7])
3 Architectural speciﬁcation
By focusing on brain tumour diagnosis and prognosis,
the HealthAgentsprojectis to apply agenttechnologyto se-
curely connect user sites with a distributed database. It will
employ agent negotiation and argumentation mechanisms
developed for distributed resource allocation problems.
Moreover, HealthAgents intends to build a completely
distributed repository with local databases. Grid tech-
nologies such as multi-site data partition and distributed
data sharing will permit the seamless access to different
databases across sites.
We argue that a d-DSS will furnish a completely new
approach to brain tumour diagnosis. Since inferences from
local predictions may well conﬂict with one another, rea-
sonedargumentbetween intelligentagents, actingon behalf
Figure 3. HealthAgents multi-layer framework)
of scientists, in a multi-agent system, will foster consensus.
TheHealthAgentsprojectintendsnotonlytoapplyagent
technology to the biomedical ﬁeld in a multi-disciplinary
fashion, but also develop the ﬁrst distributed repository for
brain tumour diagnosis, leading eventually to the formation
of a special interest data grid.
A centralised DSS is already available from the INTER-
PRET project [14, 6] to facilitate the clinical use of MRS in
brain tumour diagnosis which uses a classiﬁcation based on
histopathological diagnosis. A more elaborated DSS, com-
bining MRS biochemical proﬁles from Single Voxel (SV)
and metabolic spatial distribution by Chemical Shift Imag-
ing (CSI) MRS in vivo data, is currently being developed
and implemented in the eTUMOUR project [6]. The eTU-
MOUR DSS will eventually improve and facilitate the clin-
ical application of MRS in adults and paediatric brain tu-
mour diagnosis, prognosis and treatment selection using a
classiﬁcation based on the combination of histology results
and high resolution metabolic proﬁles (HR-MAS) and tran-
scriptomic (DNA micro-arrays) ex vivo data.
The HealthAgents d-DSS will build upon these projects
and include additional MRS data, such as childhood tu-
mours and less common adult tumours, using new classi-
ﬁcations based on genetics. The development of this new
d-DWH (the “d-DSS”), incorporating concepts of network-
ing, agent technology, and data mining, must increase the
number of accessible cases, yielding to an improved clas-
siﬁer, that in turn will achieve the goals described in this
proposal.
HealthAgentsproposesa multi-layersystem architecture
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map a relational database schema to the HealthAgents on-
tological schema. The programmingAPI layer abstracts the
underlyingdatabase interaction from the agent architecture.
The business methods layer contributes to the main control
ﬂow of an agent such as the new case classiﬁcation, new
classiﬁers reception, and data retrieval.
The security and trust layer is a crucial system compo-
nent due to the sensitivity of the data. Its functionalities are
access control, data marshalling, tracking of on-going data,
and the evaluation of reputation and trust of agents. The
agent layer is in charge of all the communications and al-
lows their abstraction from the rest of the system to allow
ﬂexibility in the underlying framework. The semantic de-
scriptionlayerwill containthe descriptionof what the agent
holds and what it is able to do.
4 Conclusions
In vivo MRS combined with in vitro MAS and gene ex-
pression promises to improve the classiﬁcation of brain tu-
mours and yield novel biomarkers for prognosis. Consider-
able amounts of highly complex data are required to build
reliable speciﬁc tumour classiﬁers and it is a challenge to
collect and manage this data. HealthAgents will address
this problem by building a distributed system of databases
centred on the users and managed by agents. As a result,
HealthAgents proposes a unique blend of state-of-the-art
technologies to develop novel clinical tools for the diagno-
sis, management and understanding of brain tumours.
We have introduced the HealthAgents project, its ob-
jectives, and scope. Although tangible results are to be
produced soon, we strongly believe that the conditions are
given to produce an innovative software system to help in
the ﬁght against one of the most pernicious diseases of our
time: cancer.
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